Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Tickers EFTR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.